Business
Oxford Biomedica to present at the ASGCT
Oxford Biomedica to present at the ASGCT.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 5978X Oxford Biomedica PLC 30 April 2019 \n\n \n \n \nOxford Biomedica to present at the Annual Meeting of the American Society of Gene & Cell Therapy \n \nOxford, UK - 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.\n \nAn oral presentation by OXB will highlight previously published preclinical data from an investigation of 5T4 expression and the potential of a CAR-T therapy, OXB-302, as a treatment for haematological and solid tissue cancers. In a separate oral presentation, details from the ongoing SUNRISE-PD Phase 1/2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease will be shared by OXB's partner, Axovant Gene Therapies.\n \nAdditional poster presentations by OXB scientists will highlight preclinical data on OXB-203, OXB's programme for wet age-related macular degeneration, as well as presentations on OXB's LentiVector® manufacturing process.\n \nDr Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica, said:\n \n\"Our scientific presence at ASGCT demonstrates the strength of our LentiVector® platform. We look forward to highlighting the potential of gene and cell therapy with lentiviral vectors, both in our own proprietary programmes and in those of our partners, to further advance our mission to deliver life-changing therapies to patients.\" \n \nOral presentations:\n \nTitle: Pre-Clinical Investigations of CAR T Cells Directed Against the Tumour Antigen 5T4 (OXB-302) in Solid Tumor Models (Abstract #373)\nSession: Immunotherapy 1\nDate and time: Tuesday, 30 April 2019, 9.45-10am ET\nNote: includes new data as well as data previously presented at the International Symposium on Immunotherapy, 12-13 May 2017 and published in the Journal of Immunotherapy*\n \nTitle: AXO-Lenti-PD: A Second-Generation Lentiviral Gene Therapy for the Treatment of Parkinson's Disease (Abstract #222)\nSession: Gene replacement for neurological diseases\nDate and time: Tuesday, 30 April 2019, 3.30-3.45pm ET\n \nPoster presentations:\n \nTitle: ...